BIOQUAL, Inc. Announces Retirement of Dave Newcomer as Chief Financial Officer, Effective June 3, 2022
May 09, 2022 at 10:47 pm IST
Share
BIOQUAL, Inc. announced that Dave Newcomer will retire from his role as Chief Financial Officer effective June 3, 2022. Newcomer will remain in his current position until then to support with the transition of his responsibilities to his successor. Newcomer's position will be filled by Charles (Chris) C. Kirk, Jr., CPA.
Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both government contracting and services oriented companies as well as in the public accounting sector. Kirk has served as Director of Finance and Accounting for BIOQUAL over the past year.
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
BIOQUAL, INC. 
